Abstract: Refractory cardiogenic shock (RCS) is associated with a high mortality. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used as acute cardiopulmonary support but selection of VA-ECMO candidates remains challenging. There are limited data on which pre-VA-ECMO variables that predict outcome. The aim of this study was to identify pre-VA-ECMO predictors of 90-day mortality. We retrospectively analyzed 76 consecutive patients (median age 52; interquartile range [IQR]: 37-60) supported with VA-ECMO due to RCS. The association between pre-implant variables and all-cause mortality at 90 days was analyzed with multivariable logistic regression. Main etiologies of RCS were acute myocardial infarction 51% and other AHF etiologies 49%. Cardiopulmonary resuscitation was performed in 54% of patients before initiation of VA-ECMO. Median duration of VA-ECMO was 5 days (IQR: 2-11). The 90-day overall mortality was 49% and in-hospital mortality was 50%; 46% died on VA-ECMO, 37% were successfully weaned, 13% were bridged to heart transplantation, and 4% to left ventricular assist device. Multivariable logistic regression analysis identified arterial lactate (odds ratio [OR] per mmol/L: 1.15; 95% confidence interval [CI]: 1.06-1.24; P = 0.001) and number of inotropes and vasopressors (OR per agent: 2.14; 95% CI: 1.26-3.63; P = 0.005) as independent predictors of 90-day mortality. In RCS patients arterial lactate level and number of inotropes and vasopressors were identified as independent pre-VA-ECMO predictors of 90-day mortality. Thus, the severity of cardiogenic shock expressed as levels of lactate and vasoactive agents just before start of VA-ECMO may be more predictive of outcome than the specific etiology of cardiogenic shock.
insertion without access to the operating room. Nonetheless, VA-ECMO is resource demanding; its initiation is often based on subjective criteria and associated with considerable risk for severe complications. Despite VA-ECMO support, RCS has an overall in-hospital mortality rate of around 50% (4, 9) . Hence, appropriate patient selection, timing for VA-ECMO initiation, and identification of pre-VA-ECMO predictors for post-ECMO survival is vital (7, 10) .
Although RCS represents the majority of patients on VA-ECMO (8) , the majority of studies have focused on postcardiotomy patients (11) (12) (13) (14) (15) (16) (17) . Remaining studies have evaluated nonsurgical subgroups (18) (19) (20) (21) (22) (23) (24) or a combination of nonsurgical and surgical populations (7, (25) (26) (27) (28) (29) , which complicates interpretation as the two latter cohorts have different pathophysiological mechanisms. Independent pre-VA-ECMO outcome predictors in an unselected nonsurgical population with RCS have only scarcely been identified as studies have mainly included variables from both before and after initiation of VA-ECMO in the analysis (30, 31) , or have not reported rates of missing data (21, 23, 24, 31, 32) or having substantially incomplete data (7, 32) . In addition, it is problematic to include variables after VA-ECMO initiation (i.e., during support) when the specific aim is to determine which patients should be selected to receive this highly invasive therapy. To our knowledge only one previous single center study has addressed pre-VA-ECMO predictors in an unselected nonsurgical population with RCS (32) . Thus, the aim of our single-center study was to identify independent pre-VA-ECMO predictors for 90-day mortality in an unselected nonsurgical population with RCS.
PATIENTS AND METHODS

Study population
We retrospectively reviewed the medical records of 76 consecutive patients, who received VA-ECMO support for RCS between October 2006 and March 2015 at our institution. Patients' characteristics including clinical presentation, interventions and the laboratory data just before VA-ECMO onset, were together with complications and outcome data obtained from the medical records. Patients undergoing VA-ECMO implantation due to noncardiac causes or postoperative RCS were not included. The Regional Ethics Review Board approved this study (project no. 2008/1695-31 and 2012/119-32) and the analysis conformed to the ethical guidelines of the 1975 Declaration of Helsinki. At present, there are no defined criteria for when to initiate VA-ECMO support in RCS. Our unit considers VA-ECMO as a salvage therapy for evidence of progressive hypoperfusion and tissue hypoxia, secondary to RCS, unresponsive to medical therapy, including adequate intravascular volume loading and support with high doses of inotropes and vasopressors. Patients were candidates for VA-ECMO support when there was a potential for recovery, heart transplantation, or as a bridge to long-term mechanical assist device (LVAD). Exclusion criteria included cerebral hemorrhage, severe aortic valve insufficiency, aortic dissection, short-life expectancy due to other medical conditions, advanced age, nonwitnessed cardiac arrest, implantation due to noncardiac causes, or postoperative RCS. All patients were considered to have negligible chance of survival without initiating VA-ECMO support. The final decision for initiation of VA-ECMO was made by the cardiothoracic intensivist, interventional cardiologist, and cardiothoracic surgeon. The device, implantation technique and patient management has been described elsewhere (9, 33) . In brief, the standard VA-ECMO procedure included cannulation of the femoral artery and vein either by surgical cut down or percutaneous puncture, along with a distal perfusion catheter to prevent limb ischemia. Central cannulation of the right atrium and ascending aorta was occasionally performed on patients because of lack of suitable peripheral vascular access (n = 2; 2.6%). The VA-circuit consisted of a centrifugal pump (CardioHelp-i, Maquet, Rastatt, Germany or Thoratec CentriMag system, Pleasonton, CA, USA), a membrane oxygenator (Maquet HLS Module Advanced) and a tubing system (Maquet Bioline) with an integrated heat exchanger. Suitable RCS patients at external hospitals were connected to VA-ECMO and transported to our institution by our mobile ECMO unit. Weaning from VA-ECMO was attempted after cardiopulmonary optimization when no further cardiac and pulmonary improvement was expected. If weaning failed, bridging to LVAD or transplantation was considered as an alternative in patients with favorable neurological prognosis. Patients with severe neurological injuries or patients where weaning failed without them being candidates for other destination therapies were weaned off VA-ECMO during withdrawal of life support.
Independent baseline variable definitions
RCS was defined as CS with evidence of progressive tissue hypoxia and end organ failure unresponsive to conventional medical therapy as specified above. The variables AMI, ischemic heart disease (IHD), chronic cardiomyopathy, chronic renal failure, numbers of inotropes and vasopressors, and pre-VA-ECMO data were defined as history of myocardial infarction, angina pectoris, percutaneous coronary intervention (PCI)/ coronary artery bypass grafting (CABG) or where prior coronary angiography had shown evidence of coronary artery disease (at a prior multidisciplinary conference), idiopathic nonischemic or ischemic cardiomyopathy, chronic kidney disease stage ≥3 (estimated glomerular filtration rate (GFR) of <60 mL/min/1.73 m 2 during ≥3 months in accordance to the US National kidney foundation KDOQI guidelines 2012), total number of intravenous inotropes and vasopressors (epinephrine, norepinephrine, dobutamine, dopamine, vasopressin, milrinone, levosimendan), and latest available clinical and laboratory data just before VA-ECMO onset, respectively. Prior data were defined as previous to the current medical event/admission. CPR included all CPR episodes within 12 h before VA-ECMO onset.
Dependent outcome definitions
The primary outcome was defined as death from any cause at 90 days after VA-ECMO initiation. Successful weaning was defined as survival more than 48 h after weaning from VA-ECMO or without need of re-initiation of VA-ECMO. Good functional outcome was defined as a score of 1-2 based on the cerebral performance category (CPC) scale.
Statistical analysis
Primary analysis compared pre-VA-ECMO variables between survivors and nonsurvivors at 90 days after initiation of VA-ECMO support. Categorical variables were presented as numbers and percentages, and compared with the Chi-square, Likelihood ratio or Fisher's exact tests. Because most continuous baseline variables were nonnormally distributed (all but BMI, weight, hemoglobin, and platelets), a conservative approach with all data expressed as median and IQR was taken, and compared with the Mann-Whitney U-test. A univariable logistic analysis was used to determine the pre-VA-ECMO-implant variables for death at 90 days after VA-ECMO initiation. Statistical significance was set at P < 0.05. Variables identified as being significant in the univariable analysis were subjected to multicollinearity analysis using the Spearman's rho correlation coefficient prior to multivariable logistic regression analysis. Two variables, none with missing data, were included in the multivariable logistic regression model to determine the independent associations between pre-VA-ECMO-implant variables and 90-day mortality. To assess the impact of nonlinearity on the logistic regression analysis the continuous variables included in the model were tested using restricted cubic splines (the restricted cubic spline analysis is presented in the Supporting Information S2). Goodness of fit was verified by the HosmerLemeshow's test indicating that the number of deaths was not significantly different from those predicted by the model and that the overall fit of the model was good. A cumulative survival curve for 90 days follow-up was generated utilizing the Kaplan-Meier method and compared using the log rank test. All statistical analyses were performed with SPSS version 25 for Windows (IBM SPSS Statistics, Armonk, NY, USA).
RESULTS
No patients were lost to follow-up and there were no VA-ECMO device-related deaths. Pre-VA-ECMO variables and comparison between survivors and nonsurvivors at 90 days after initiation of VA-ECMO support are summarized in Table 1 , with significant differences including arterial lactate, arterial pH, MAP, and number of inotropes and vasopressors just before cannulation. Median age was 52 years (IQR: 37-60), which was not significantly lower between survivors (50 years; IQR: 36-58) compared with nonsurvivors (55 years; IQR: 47-60; P = 0.194). Three patients were older than 70 years (oldest was 76); all were survivors at 90 days. AMI was the most common (mutually exclusive) etiology for VA-ECMO support (n = 39; 51%) followed by AHF of other etiologies (n = 37; 49%): acute deterioration of chronic cardiomyopathy (n = 13; 17% including idiopathic nonischemic cardiomyopathy n = 9; 12% and ischemic cardiomyopathy n = 4; 5.3%), acute myocarditis (n = 10; 13%), acute pulmonary embolus (n = 3; 4%), intoxication (n = 3; 4%), septic cardiomyopathy (n = 3; 4%), peripartum cardiomyopathy (n = 2; 2.6%), severe hypothermia (n = 1; 1.3%), endocarditis (n = 1; 1.3%), and congenital pulmonary valve stenosis (n = 1; 1.3%). Prior to VA-ECMO implantation, primary PCI, CPR, and support with intra-aortic balloon pump (IABP) were performed in 47% (n = 36), 54% (n = 41) and 24% of patients (n = 18), respectively. In 10 patients the IABP was removed at VA-ECMO initiation, thereby leaving the IABP in eight patients during VA-ECMO support. Renal replacement therapy (RRT) was initiated in seven patients (9%) prior to VA-ECMO and in another 22 patients (29%) during VA-ECMO, giving in all 35 patients (46%) supported with RRT during VA-ECMO. All patients (n = 76) were mechanically ventilated at implantation. Patients were cannulated in the operating room (n = 47; 62%, P = 0.955), ICU (n = 18; 24%, P = 0.341), and in the catheterization laboratory (n = 11; 15%, P = 0.283), without having a significant influence on 90-day mortality. A distal perfusion catheter was inserted in 76% (n = 56) of patients with peripheral cannulation (n = 74; 97%). No other mechanical support systems were inserted. In the univariable logistic regression analysis, four variables were significantly associated with 90-day mortality: arterial lactate, arterial pH, number of inotropes and vasopressors, and MAP (Table 2 ).
In the multivariable logistic regression analysis, two variables remained significant after pH and MAP had been excluded due to high correlation with lactate (ρ = −0.759; P < 0.001 and ρ = −0.662; P < 0.001, respectively), with the strongest being arterial lactate (odds ratio [OR] per mmol/L: 1.15; 95% confidence interval [CI]: 1.06-1.24; P = 0.001), followed by the number of inotropes and vasopressors (OR per agent: 2.14; 95% CI: 1.26-3.63; P = 0.005). The restricted cubic splines analysis indicated that a nonlinearity did not impact the logistic regression analysis which supports the use of the model (the interpretation of the restricted cubic spline analysis is presented in Supporting Information S2). The WBC, white blood cell counts. * Acute decompensated chronic cardiomyopathy (n = 13), acute myocarditis (n = 10), intoxication, acute pulmonary embolus, septic cardiomyopathy (each n = 3), peripartum cardiomyopathy (n = 2), prolonged hypothermia, endocarditis, congenital pulmonary valve stenosis (each n = 1). † Prior to current medical event/admission. ‡ Just before cannulation. § Epinephrine, norepinephrine, dobutamine, dopamine, vasopressin, milrinone, levosimendan.
TABLE 1. Continued
full model, containing the independent predictors, was statistical significant, χ 2 (df = 2, n = 76) =21.433; P < 0.001, indicating that the model was able to distinguish between survivors and nonsurvivors at 90 days. The χ 2 for Hosmer-Lemeshow's Test was 6.293 with a significance level of P = 0.614 thereby supporting our model. As shown in Table 2 both independent variables made a unique statistical AHF, acute heart failure; AMI, acute myocardial infarction; CMP, cardiomyopathy; LVAD, left ventricular assist device; MD, missing data. * Acute decompensated chronic cardiomyopathy (n = 13), acute myocarditis (n = 10), intoxication, acute pulmonary embolus, septic cardiomyopathy (each n = 3), peripartum cardiomyopathy (n = 2), prolonged hypothermia, endocarditis, congenital pulmonary valve stenosis (each n = 1). † Stroke, fatal anoxia, brain death. ‡ Sudden cardiac arrest, myocardial infarction, heart failure. § Lung, gastrointestinal, retroperitoneal. ‖ Terminal emphysema.
significant contribution to the model (all variables subjected to logistic regression analysis are presented in Supporting Information Table S1 ). The sensitivity of the model was 70% (true positives) and its specificity was 67% (true negatives), giving a positive and negative predictive value of 67 and 70%, respectively. Outcome data including events after VA-ECMO initiation and causes of death within 90 days are presented in Table 3 . The median duration on VA-ECMO was 5 days (IQR: 2-11; 1-51). Death during VA-ECMO support occurred in 46% (n = 35) of the patients, 37% (n = 28) were successfully weaned, 17% (n = 13) did not tolerate weaning, 13% (n = 10) were bridged to heart transplantation, and 4% (n = 3) were bridged to LVAD. The in-hospital mortality was 50% (n = 38) and 50% (n = 38) were discharged to home. The mortality rate after 24, 48, 72 h, 7, 30, 90 days, and 18 months were 16, 22, 24, 33, 42, 49 , and 51%, respectively. Of the 38 patients discharged to home, all had a good cerebral functional outcome score, defined as a score of 1-2 according to the CPC scale. Multiple organ failure was the main cause of death on VA-ECMO 51% (18 of 35 deaths), as well as within 90 days after initiation of VA-ECMO 49% (18 of 37 deaths) .
The main complications after initiation of VA-ECMO are shown in Fig. 1 with the most frequent being renal failure necessitating hemodialysis (46%), pneumonia (38%), sepsis (25%), and brain death or fatal anoxia (16%). Figure 2 depicts the cumulative Kaplan-Meier survival curves until 90 days after initiation of VA-ECMO related to the arterial lactate intervals, indicating that the higher the initial arterial lactate level, the worse the outcome (P < 0.001). All three curves present a significant drop in survival most prominent within the first 10 days after initiation of VA-ECMO. All patients (8/8) with a pre-VA-ECMO lactate level higher than 20 mmol/L died within 6 days after initiation of VA-ECMO.
DISCUSSION
This single-center study identified arterial lactate and number of vasopressors and inotropes as independent pre-VA-ECMO predictors for 90-day mortality in an unselected population with RCS supported by VA-ECMO.
In the setting of RCS, arterial lactate level is an indicator of the degree of general tissue hypoperfusion, secondary to a low cardiac output resulting in impaired tissue oxygenation, anaerobe metabolism and end-organ failure (34, 35) . The worse the tissue hypoperfusion is, the higher the lactate and risk for mortality (13, 36) . Moreover, metabolic acidosis will be treated with intravenous bicarbonate, which will influence base excess and arterial pH but not arterial lactate. Equally, arterial lactate will not be in influenced by arterial carbon dioxide pressure levels, whereas arterial pH will. Arterial lactate has in agreement with our study also been found to be an independent pre-VA-ECMO predictor of short and midterm survival in several other studies with selected or unselected patients' populations (10, 21, 23) . Our finding of an odds ratio of 1.15 per mmol/L implies that the mortality risk increases 10-fold at a lactate level of 10 mmol/L. A further important feature that strengthens the impact of arterial lactate as a predictor to assess before initiation of VA-ECMO was that we were able to identify that specific intervals of arterial lactate levels progressively indicated worse outcomes as presented in the Kaplan-Meier survival curves (Fig. 2) .
The pharmacological approach to initially counteract RCS is administration of intravenous inotropes and vasopressors (3), often combined, which was also found to be a strong independent predictor of 90-day mortality. This is in line with previous studies describing that the degree of vasoactive support may have a role as an outcome predictor in different ECMO and non-ECMO settings (12, 37, 38) . Since lactate and number of inotropes and vasopressors were independent of one another, it is likely that there are numerous aspects of RCS and need of vasoactive drug support that is reflected in the role of number of inotropes and vasopressors in predicting outcomes. To our knowledge this study is the first to present that the number of inotropes and vasopressors at initiation of VA-ECMO independently predicts survival at 90 days in nonsurgical adults with RCS, although we have reported similar findings in a population that, however, included surgical patients (25) . Despite AMI being the most frequent reason for CS in other studies (2,4,39) we were not able to identify AMI per se as an independent predictor of 90-day mortality in with RCS, even if patients with cardiovascular disease generally have worse expected outcomes (25, 40) . Hence, it must be recognized that neither AMI per se nor the cohort of other nonsurgical etiologies were significantly associated with mortality after initiation of VA-ECMO, which is in coherence with the recent single center study by Waha et al. (32) . Thus, the severity of cardiogenic shock expressed as levels of lactate and vasoactive agents just before start of VA-ECMO may be more predictive of outcome than the specific etiology of cardiogenic shock. This important finding has clinical implications. Most likely, it seems prudent to proceed rapidly to VA-ECMO in suitable patients with RCS before severe lactate acidosis and need of increasing number of vasoactive drug support develops. Moreover, this further implies cautiousness to consider etiology when deciding which patients may benefit from ECMO support, as decisions often have to be made rapidly without sufficient time to obtain complete information of the patients' background. Clearly, an efficient logistic pathway in the decision making and cannulation strategy should further shorten the time from decision to established VA-ECMO support.
Previous larger studies have presented a combination of nonsurgical and surgical patients (7, (25) (26) (27) (28) (29) including both predictors before and during VA-ECMO (30,31), or have not reported rate of missing data (21, 23, 24, 31, 32) or having substantially incomplete data (7, 32) . The largest and only single center study strictly addressing the impact of pre-ECMO variables on outcome by Waha et. al. (32) , included unselected patients with RCS receiving VA-ECMO without prior surgery. It had several similarities with our study: the number of included patients (n = 83): rates of PCI in AMI patients (93%), pre-ECMO CPR (55%), bridge to transplantation (3.6%), proportion of males (74%), VA-ECMO duration (median 6 days), and death during VA-ECMO (43%) compared to 76 patients, 92%, 54%, 3.9%, 74%, median 5 days, and 46% in our study. The higher in-hospital and 18-month mortality reported by Waha et al. (81.9%) compared with our study (51%) may partly be explained by an older study population (median age was 9 years higher, all 14 patients above 75 years died prior to hospital discharge) and a higher prevalence of cardiovascular comorbidity (AMI 64% vs. 51%) compared with our study cohort. An unexpected and not commented finding by Waha et al. (32) was a higher pre-VA-ECMO lactate level among survivors compared with nonsurvivors, which is in stark contrast to our results and previous publications on nonsurgical RCS (21, 23, 26) . Thus, the most likely explanation is that arterial lactate was only sampled in relatively stable patients and not in unstable RCS patients with a more pronounced oxygen deficit (rate of missing data not presented). This possible selection bias may thereby be explained by incomplete data, where a high proportion of missing data, not absent at random, may lead to unreliable results. In comparison, all variables tested in our multivariate analysis were complete and thus arterial lactate, an indicator of severe tissue hypoperfusion, became a strong independent predictor of mortality.
The primary endpoint mortality within 90 days after initiation of VA-ECMO in our study was chosen over 30-day mortality, as 7.9% of the patients (n = 6) had VA-ECMO support ≥30 days. Also, the Kaplan-Meier survival curves flattened out before reaching 90 days (Fig. 2) . Given the nonproportional hazards with early high risk, we preferred logistic regression for categorical vital status at 90 days rather than Cox regression for time-dependent outcomes analyses. Moreover, we preferred the outcome variable mortality at 90 days (49%) to the alternative alive at hospital discharge (50%) as the former includes a specific time span. Indeed, the mortality rate was almost identical for hospital discharge and for 90 days.
Only a few single-center studies in patients with nonsurgical RCS supported with VA-ECMO have identified age as being a significant outcome predictor. In contrast to the studies by Waha et al. (32) and Muller et al. (23) , age did not reach significance in our multivariate analysis (P = 0.252). This could be a Type II error, but more likely suggest that in previous less adjusted analyses, age was important, whereas in our analyses, age was neutralized by the covariates included in the model.
Limitations
This retrospective observational study with a heterogeneous patient population did not allow for randomization or include a matched control cohort. However, its heterogeneity reflects the clinical reality in centers providing nonsurgical RCS patients VA-ECMO support and thereby provides for external validity (generalizability) of our findings. Even though this study population is one of the largest described so far, the number of patients is relatively small, and thus our findings may not allow definitive recommendations.
CONCLUSION
In patients with refractory cardiogenic shock, arterial lactate level and number of inotropes and vasopressors were identified as independent pre-VA-ECMO predictors of 90-day mortality. Thus, the severity of cardiogenic shock expressed as levels of lactate and vasoactive agents just before start of VA-ECMO may be more predictive of outcome than the specific etiology of cardiogenic shock. Despite being resource demanding and associated with risks for severe complications, VA-ECMO can offer significant chance of 90-day survival in these patients with otherwise dismal futile prognosis. VA-ECMO should be considered before profound hyperlactatemia occurs and the number of inotropes and vasopressors has increased. 
